Susan O’Brien

University of California, Irvine — United States

Medicine · Health Sciences

122h-index52.7kcitations1.2kworks5.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(708), Chronic Myeloid Leukemia Treatments(500), Acute Lymphoblastic Leukemia research(410), Acute Myeloid Leukemia Research(322), Lymphoma Diagnosis and Treatment(285)

Publications1.2k total

71 | FINAL ANALYSIS OF FIXED‐DURATION IBRUTINIB + VENETOCLAX FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL) IN THE PHASE 2 CAPTIVATE STUDY
Hematological Oncology·2025· 2 citedOpen Access
214 | FINAL INDEPENDENT REVIEW DATA SUPPORTS SUSTAINED BENEFIT OF ZANUBRUTINIB OVER IBRUTINIB IN PATIENTS WITH R/R CLL/SLL IN ALPINE
Hematological Oncology·2025· 1 citedOpen Access
Ibrutinib Efficacy Across Subgroups of Patients With High-Risk Chronic Lymphocytic Leukemia: A Systematic Literature Review
Clinical Lymphoma Myeloma & Leukemia·2024
CLL-481 Ibrutinib Efficacy Across Subgroups of Patients With High-Risk Chronic Lymphocytic Leukemia: A Systematic Literature Review
Clinical Lymphoma Myeloma & Leukemia·2024· 1 citedOpen Access
CLL-057 Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib (Ibr) + Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study
Clinical Lymphoma Myeloma & Leukemia·2024· 1 citedOpen Access
Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison
Blood Cancer Journal·2024· 5 citedOpen Access
Chronic myelogenous leukemia
2024· 11 citedOpen Access
Long-Term Follow up for SWOG 1318: Combination of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia-Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)
Blood·2023· 12 cited
Incidence and Management of COVID-19 Infections in Vaccinated Patients with CLL
Blood·2023Open Access
The Blessed Virgin Mary
2023· 15 cited
Evidence-Based Management of Chronic Lymphocytic Leukemia: Consensus Statements from the Gulf Region
Acta Haematologica·2023· 1 cited
Phase II trial of mini-hyper-CVD-inotuzumab (InO) followed by blinatumomab (blina) consolidation in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).
Journal of Clinical Oncology·2023
Treatment outcomes in adults with newly diagnosed B-cell acute lymphoblastic leukemia: A comparison between pediatric-inspired regimens and HyperCVAD at a Hispanic-serving cancer center.
Journal of Clinical Oncology·2023
Supplementary Table 1 from Constitutive Phosphorylation of STAT3 by the CK2–BLNK–CD5 Complex
2023Open Access
Supplemental Table 1 from Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells
2023Open Access
Supplementary Table 1 from Constitutive Phosphorylation of STAT3 by the CK2–BLNK–CD5 Complex
2023Open Access
Supplemental Table 1 from Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells
2023Open Access
Data from Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells
2023Open Access
Data from Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells
2023Open Access
Supplemental Files_Clean version from Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia
2023Open Access
page 1 of 61Next →

Frequent Co-authors

Hagop M. Kantarjian(45), Jörge E. Cortes(36), Guillermo Garcia‐Manero(21), Stefan Faderl(20), Michael J. Keating(20), Deborah A. Thomas(20), Francis J. Giles(17), William G. Wierda(17), Farhad Ravandi(17), Elias Jabbour(15), Alessandra Ferrajoli(12), Charles Koller(10), Srđan Verstovšek(10), Marina Konopleva(10), Zeev Estrov(9), Jianqin Shan(9), Sherry Pierce(9), Michael Andreeff(7), Jeffrey L. Jorgensen(7), Dan Jones(7)